Literature DB >> 9136960

Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation.

A Atra1, B Millar, V Shepherd, A Shankar, K Wilson, J Treleaven, K Pritchard-Jones, S T Meller, C R Pinkerton.   

Abstract

Four children with acute lymphoblastic leukaemia (ALL) who relapsed after allogeneic bone marrow transplantation (BMT) were treated with donor lymphocyte infusion (DLI) without prior conditioning. Three patients had previously received a non-T-cell-depleted matched sibling BMT and the fourth had a T-cell-depleted matched unrelated BMT. Two patients developed grade III-IV acute graft-versus-host-disease (GVHD) of the skin, which required intervention. Both are alive in complete haematological remission 7 and 10 months from DLI with chronic GVHD of the skin requiring immunosuppressive therapy. A third patient went into haematological remission 6 weeks after DLI, but with no clinical evidence of GVHD. His bone marrow remained in remission 11 months post-DLI despite the disease (ALL) relapsing in extramedullary sites. The fourth patient showed no clinical or haematological response to three consecutive doses of DLI given at 4-weekly intervals and died from progressive disease 11 months after relapse. These preliminary observations indicate that in constrast to experience in adult ALL, DLI may be effective in inducing sustained remission in children with ALL relapsing after BMT, and a response may occur even in the absence of clinical evidence of GVHD.

Entities:  

Mesh:

Year:  1997        PMID: 9136960     DOI: 10.1046/j.1365-2141.1997.62650.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  Hematopoietic stem cell transplantation for leukemia.

Authors:  Alan S Wayne; Kristin Baird; R Maarten Egeler
Journal:  Pediatr Clin North Am       Date:  2010-02       Impact factor: 3.278

2.  NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  David L Porter; Edwin P Alyea; Joseph H Antin; Marcos DeLima; Eli Estey; J H Frederik Falkenburg; Nancy Hardy; Nicolaus Kroeger; Jose Leis; John Levine; David G Maloney; Karl Peggs; Jacob M Rowe; Alan S Wayne; Sergio Giralt; Michael R Bishop; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

3.  Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC.

Authors:  Paul Chauvet; Annalisa Paviglianiti; Myriam Labopin; Hélène Labussière; Nicolas Boissel; Marie Robin; Natacha Maillard; Marie Ouachée-Chardin; Edouard Forcade; Xavier Poiré; Sylvain Chantepie; Anne Huynh; Claude Eric Bulabois; Mathieu Leclerc; Sébastien Maury; Patrice Chevallier; Thomas Cluzeau; Jean-Baptiste Mear; Jérôme Cornillon; Karin Bilger; Célestine Simand; Yves Beguin; Marie-Thérèse Rubio; Ibrahim Yakoub-Agha; Eolia Brissot
Journal:  Bone Marrow Transplant       Date:  2022-10-19       Impact factor: 5.174

Review 4.  When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Adam Lamble; Rachel Phelan; Michael Burke
Journal:  J Clin Med       Date:  2017-07-07       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.